PDF(Sci-hub)
Abstract：
This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes.
Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking.
All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.
Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking.
All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.
摘要：
该联合实践指南或程序标准是由欧洲核医学协会（EANM）和核医学与分子成像协会（SNMMI）合作开发的。本指南的目标是帮助核医学从业者推荐，表演,口译,并报告帕金森病综合征的多巴胺能成像结果。
目前的核医学研究可以评估多巴胺能突触的突触前和突触后功能。迄今为止，EANM和SNMMI均已发布了使用单光子发射计算机断层扫描（SPECT）进行多巴胺转运蛋白成像的程序指南（分别于2009年和2011年）。D2SPECT成像的EANM指南也可用（2009年）。自从这些以前的指南发布以来，在半量化方面已经有了新的证据，协调,与正常数据集的比较，和SPECT多巴胺转运蛋白成像的纵向分析。同样，关于采集协议和简化量化方法的详细信息现在可用于PET多巴胺转运蛋白成像，包括最近开发的氟化示踪剂。最后,[18F]氟多巴PET现在在某些中心用于帕金森病的鉴别诊断，尽管仍然缺乏旨在定义这种情况下[18F]荧光多巴成像标准程序的程序指南。
所有这些新出现的问题都在目前帕金森病综合征多巴胺能成像的程序指南中得到解决。
目前的核医学研究可以评估多巴胺能突触的突触前和突触后功能。迄今为止，EANM和SNMMI均已发布了使用单光子发射计算机断层扫描（SPECT）进行多巴胺转运蛋白成像的程序指南（分别于2009年和2011年）。D2SPECT成像的EANM指南也可用（2009年）。自从这些以前的指南发布以来，在半量化方面已经有了新的证据，协调,与正常数据集的比较，和SPECT多巴胺转运蛋白成像的纵向分析。同样，关于采集协议和简化量化方法的详细信息现在可用于PET多巴胺转运蛋白成像，包括最近开发的氟化示踪剂。最后,[18F]氟多巴PET现在在某些中心用于帕金森病的鉴别诊断，尽管仍然缺乏旨在定义这种情况下[18F]荧光多巴成像标准程序的程序指南。
所有这些新出现的问题都在目前帕金森病综合征多巴胺能成像的程序指南中得到解决。
